$175.00 USD
Ver más detalles
Descripcion
Indice
Autores
Muestra
Ficha Técnica
Descripción

Some of the more recent efforts in tuberculosis (TB) and trypanosomiasis drug discovery from both Product Development Partnerships (PDPs) and academia are highlighted in this this volume. Drug discovery approaches include both target- and phenotypic whole cell screening- approaches. Regarding the latter, mechanism of action studies through target identification are also illustrated.

  • Provides an overview of the status of some of the current novel compounds in development as well as new emerging treatment options targeting novel mechanisms of action
  • Identification of hits from phenotypic whole cell screening, followed by target identification
  • Strategies aimed at improving the efficacy of existing clinically used anti-TB drugs by taking advantage inhibitors of mycobacterial transcriptional regulators to boost the anti-tubercular activity, and circumvent acquired-resistance

1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Contributors - p. ix 6. Preface - p. xi 7. Chapter One: Tuberculosis - p. xii 8. Chapter Two: Antituberculosis agents: Beyond medicinal chemistry rules - p. 25 9. Chapter Three: Development of MmpL3 inhibitors for tuberculosis treatment - p. 69 10. Chapter Four: Inhibitors of enzymes in the electron transport chain of Mycobacterium tuberculosis - p. 96 11. Chapter Five: Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance - p. 130 12. Chapter Six: Sustainable anti-trypanosomatid drugs: An aspirational goal for medicinal chemistry - p. 152

Descripcion
Descripción

Some of the more recent efforts in tuberculosis (TB) and trypanosomiasis drug discovery from both Product Development Partnerships (PDPs) and academia are highlighted in this this volume. Drug discovery approaches include both target- and phenotypic whole cell screening- approaches. Regarding the latter, mechanism of action studies through target identification are also illustrated.

  • Provides an overview of the status of some of the current novel compounds in development as well as new emerging treatment options targeting novel mechanisms of action
  • Identification of hits from phenotypic whole cell screening, followed by target identification
  • Strategies aimed at improving the efficacy of existing clinically used anti-TB drugs by taking advantage inhibitors of mycobacterial transcriptional regulators to boost the anti-tubercular activity, and circumvent acquired-resistance

1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Contributors - p. ix 6. Preface - p. xi 7. Chapter One: Tuberculosis - p. xii 8. Chapter Two: Antituberculosis agents: Beyond medicinal chemistry rules - p. 25 9. Chapter Three: Development of MmpL3 inhibitors for tuberculosis treatment - p. 69 10. Chapter Four: Inhibitors of enzymes in the electron transport chain of Mycobacterium tuberculosis - p. 96 11. Chapter Five: Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance - p. 130 12. Chapter Six: Sustainable anti-trypanosomatid drugs: An aspirational goal for medicinal chemistry - p. 152

Indice
Autores
Muestra
Ficha Técnica